Nigeria, Barbados Back $32m Pharma Plant

Nigeria and Barbados signed agreements at the 2026 Commonwealth summit to fund local IV fluid production.

The story, at a glance

Nigeria, Barbados and Afreximbank agreed to a $32 million plan for an intravenous fluids factory in Barbados.
The facility aims to produce 12 million units annually, with operations starting in 2029.

Nigeria, Barbados and the African Export-Import Bank have moved forward with a $32 million plan to build a pharmaceutical plant in the Caribbean island nation. AllAfrica reported that the project will manufacture intravenous fluids, with an initial capacity of 12 million units per year. The arrangement includes the two national governments, Barbados Pharmaceutical Inc., Nigerian firm AMA Medical Manufacturing and the development bank.

Agreements were finalized during the 2026 Commonwealth Heads of Government Meeting in Antigua and Barbuda. According to AllAfrica, Barbados Pharmaceutical Inc. and AMA Medical Manufacturing executed a memorandum of understanding. Separately, AMA and Afreximbank signed a term sheet for a Project Preparation Facility. This document represents the initial phase of a broader financial package that may include senior debt, working capital and risk-sharing tools.

Barbadian Prime Minister Mia Amor Mottley viewed the deal as a move toward economic resilience. She stated, "Barbados may be a small island state, but our ambitions for our people and our region are not small." Nigerian official Senator George Akume emphasized the industrial cooperation between the two regions. World Trade Organization head Dr Ngozi Okonjo-Iweala characterized the project as a practical example of South-South trade diversification.

The facility is scheduled to begin operations in 2029, pending feasibility studies and regulatory clearances. This effort expands on existing commercial ties, as AMA delivered its first IV fluid shipment to Barbados in March 2026. Future deliveries are planned for other Caribbean territories. Barbados also passed a law in June 2026 to create a dedicated medical products authority, which is now being implemented.

The new plant is intended to anchor wider industrial growth in the sector. AllAfrica noted that the project will proceed through feasibility, financing and regulatory stages before construction starts. The initiative aims to enhance local skills, regulatory capacity and market access for essential medicines.

Afreximbank and two governments back $32m Caribbean drug plant

The story, at a glance

Sources and further reading